fda approval of tirzepatide for weight loss Grants a New Indication Obesity Management The New FDA-Approved Game Changer

The goal is to soften, not remove

Some countries have moved to ban it

Long-term success with Tirzepatide for weight management hinges on sustainable lifestyle habits

Male C57Bl6 mice subjected to experimental myocardial infarction and treated with the CXCR4 inhibitor AMD3100 (1.25 mg/kg/d), in combination with diprotin A (70 mg/kg twice daily) and G-CSF (100 g/kg/d), demonstrated an increase in infarct size 30 days after myocardial infarction, suggesting that the beneficial effects observed were mediated directly through a SDF-1/CXCR4 signaling axis (186)

The dose of injectable semaglutide can be further increased to 1 mg once weekly if needed to achieve adequate glycemic control

A number of reports have found that the prevalence of PCOS is significantly higher in women with IIH women compared with the general female population (up to 57% compared with 5%10%)